

          -  Hypersensitivity to darunavir, colibrestat, or any excipients

          -  Patients with severe liver injury (Child-Pugh Class C)

          -  Concomitant medications that are highly dependent on CYP3A clearance, and the elevated
             plasma concentrations are associated with serious or life-threatening events.

          -  Subjects were considered to be unable to complete the study, or not suitable for the
             study by researchers

        Exit criteria:

          -  Subjects asked to withdraw the study

          -  Subject will benefit if withdraw according to researchers' suggestions
      